Leading Companies in China Ozempic Market | Top Market Leaders 2026

Leading Companies in China Ozempic Market

China ozempic market is characterized by a pivotal shift from the monopoly of multinational innovators to a highly competitive landscape involving domestic biosimilar developers. Major market players include Novo Nordisk, Hangzhou Jiuyuan Gene Engineering, Innovent Biologics, and Eli Lilly.

China Ozempic Market Overview

According to 6Wresearch, the China ozempic market is entering a period of rapid expansion and price recalibration as it integrates into the broader GLP-1 (Glucagon-like Peptide-1) receptor agonist sector. Driven by a population with over 140 million diabetes patients and a surging demand for weight-loss solutions, the market is shifting toward long-acting injectables and oral solid dosage forms. Under the supervision of the National Medical Products Administration (NMPA), the focus is moving from simple glycemic control to whole-body health, including cardiovascular and renal protection.

Competitive Landscape

The competitive landscape of the China ozempic market is defined by a race for "first-to-market" biosimilars and next-generation dual-agonist therapies. Multinational corporations are countering domestic pressure by localized manufacturing investments and label expansions, while Chinese biotech firms are leveraging high-speed clinical execution to secure National Reimbursement Drug List (NRDL) inclusions. Innovation is currently centered on extending dosing intervals moving from weekly to monthly injections and the development of non-peptide oral formulations.

Below is a list of leading players operating in the China Ozempic Market:

1. Novo Nordisk A/S

The global originator of semaglutide, maintaining dominant market share with Ozempic and Wegovy, while aggressively defending its IP and expanding indications for chronic kidney disease in China.

2. Hangzhou Jiuyuan Gene Engineering Co., Ltd.

A pioneer in the domestic sector, Jiuyuan Gene was the first to apply for a semaglutide biosimilar (Jiyoutai) approval in China, positioning itself to lead the post-patent market in 2026.

3. Innovent Biologics, Inc.

Notable for Mazdutide, a dual GLP-1/GCG receptor agonist licensed from Eli Lilly, which has shown superior weight-loss efficacy in Chinese clinical trials compared to traditional semaglutide.

4. Eli Lilly and Company

A primary rival to Novo Nordisk, Lilly is investing $3 billion into a localized China supply chain to produce orforglipron, its highly anticipated oral weight-loss pill.

5. Sino Biopharmaceutical Limited

A major pharmaceutical conglomerate that has rapidly advanced its internal semaglutide biosimilar into Phase III trials to capture the massive demand in public hospital tenders.

6. CSPC Pharmaceutical Group Ltd.

Partnered with AstraZeneca for global rights, CSPC focuses on "LiquidGel" technology for once-monthly dosing, aiming to solve patient adherence issues in the Chinese market.

7. Livzon Pharmaceutical Group Inc.

Utilizing its expertise in recombinant protein technology, Livzon has completed head-to-head Phase III trials against Wegovy to validate its domestic semaglutide injectable.

8. Hengrui Pharmaceuticals Co., Ltd.

One of China’s largest pharma firms, Hengrui is developing a robust metabolic pipeline, including HRS9531, a next-generation GLP-1/GIP dual agonist for weight loss and T2D.

9. Gan & Lee Pharmaceuticals

Leveraging its status as China's insulin leader, Gan & Lee is developing Bofanglutide, aiming to provide the first domestic once-monthly GLP-1 RA for long-term weight maintenance.

10. AstraZeneca China

AstraZeneca competes in the metabolic space through strategic collaborations with local firms like CSPC to bring novel weight-management therapies to the Chinese population.

11. Zai Lab Limited

An innovative bridge company that identifies and licenses global metabolic breakthrough therapies for accelerated clinical development and commercialization in China.

12. Tencent Healthcare

Plays a critical digital role by partnering with firms like Eli Lilly and Novo Nordisk to provide AI-driven patient management and "smart" insulin/GLP-1 tracking tools.

13. Beijing Minhai Biotechnology Co., Ltd.

While a vaccine specialist, its parent company (Kangtai) has diversified into high-end peptide manufacturing to support the domestic GLP-1 supply chain.

14. Zydus Lifesciences

A key international generic player that monitors the China patent landscape to introduce affordable semaglutide alternatives once legal barriers clear in 2026.

15. Shanghai United Imaging Healthcare

Provides the diagnostic infrastructure, including advanced PET-CT and MRI, used in clinical trials to monitor the metabolic impact and visceral fat reduction of Ozempic-class drugs.

Leading Companies in China Ozempic Market: FAQs